Boston An independent LDT provider
OBS:Immunovia har upphört med kommersialiseringen av IMMray PanCan-d-testet. Mer information finns här:

Immunovia announces updated financial calendar for financial year 2023

mars 22, 2023

LUND (SWEDEN) – Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2023 and 2024.


May 23, 2023  Q1 2023

August 23, 2023 Q2 2023

November 9, 2023 Q3 2023

February 21, 2024 Year-end report 2023


The Annual General Meeting will be held on May 26, 2023.


For more information, please contact:
Karin Almqvist Liwendahl
+46 70 911 56 08


About Immunovia 
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.

Our first product, IMMray™ PanCan-d is the only blood test currently available for early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see:

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups. 

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world’s largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit 

Press release (PDF)